Raub Brock Capital Management LP Increases Position in Pfizer Inc. (NYSE:PFE)

Posted by Defense World Staff on Jul 3rd, 2023

Raub Brock Capital Management LP increased its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 55.1% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,851 shares of the biopharmaceutical company’s stock after purchasing an additional 3,500 shares during the quarter. Raub Brock Capital Management LP’s holdings in Pfizer were worth $402,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in PFE. Lam Group Inc. acquired a new stake in shares of Pfizer during the 4th quarter worth about $25,000. Worth Asset Management LLC acquired a new stake in shares of Pfizer during the 1st quarter worth about $29,000. My Personal CFO LLC acquired a new stake in shares of Pfizer during the 4th quarter worth about $32,000. Mendota Financial Group LLC acquired a new stake in shares of Pfizer during the 4th quarter worth about $33,000. Finally, Delos Wealth Advisors LLC boosted its stake in shares of Pfizer by 100.0% during the 3rd quarter. Delos Wealth Advisors LLC now owns 800 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 400 shares during the last quarter. Hedge funds and other institutional investors own 67.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Daiwa Capital Markets cut shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $38.00 price target on the stock. in a research note on Thursday, May 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Pfizer in a report on Wednesday, May 17th. Morgan Stanley cut their price objective on shares of Pfizer from $45.00 to $44.00 and set an “equal weight” rating on the stock in a report on Monday, April 10th. Wells Fargo & Company cut their price objective on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a report on Friday, March 17th. Finally, Barclays cut their price objective on shares of Pfizer from $43.00 to $40.00 in a report on Wednesday, May 3rd. Eleven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $46.67.

Pfizer Trading Up 1.6 %

PFE opened at $36.68 on Monday. The firm has a market capitalization of $207.07 billion, a P/E ratio of 7.22, a P/E/G ratio of 1.22 and a beta of 0.61. The firm’s 50 day moving average is $38.32 and its 200-day moving average is $42.05. Pfizer Inc. has a 52-week low of $35.76 and a 52-week high of $54.93. The company has a quick ratio of 1.11, a current ratio of 1.37 and a debt-to-equity ratio of 0.31.

Pfizer (NYSE:PFE – Free Report) last posted its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.23. The company had revenue of $18.28 billion for the quarter, compared to analyst estimates of $16.49 billion. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. The business’s quarterly revenue was down 28.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.62 earnings per share. Analysts expect that Pfizer Inc. will post 3.35 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 5th. Stockholders of record on Friday, July 28th will be given a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 4.47%. The ex-dividend date of this dividend is Thursday, July 27th. Pfizer’s payout ratio is currently 32.28%.

Insider Transactions at Pfizer

In related news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction dated Monday, May 8th. The stock was acquired at an average price of $38.58 per share, with a total value of $38,580.00. Following the completion of the transaction, the director now owns 6,000 shares of the company’s stock, valued at $231,480. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.05% of the company’s stock.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.